Astrazeneca Ab

Zeneca Limited

Nicholas John Newcombe

Andrew Peter Thomas

David Waterson

Howard Tucker

George R Brown

Bernard Christophe Barlaam

Robert I Dowell

Maurice Raymond Verschoyle Finlay

Gloria Anne Breault

Robin Wood

Elaine Sophie Elizabeth Stokes

John Graham Cumming

David William Heaton

William J Watkins

Elaine Sophie Stokes

Christophe B Barlaam

Michael Clyde Johnson

Alan John Foubister

Maurice R V Finlay

Robert Ian Dowell

Compounds of the formula (I), wherein R, R, R, R, Rand p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man. 

Pyrimidine compounds

Compounds of the formula (I): wherein R, R, R, R, Rand p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man. 

Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity

Compounds of the formula (I) wherein R, R, R, R, R, Rand p are as defined within and pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man. 

Compounds of the formula (I): wherein R, R, R, R, Rand p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13 

Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)

Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Metalloproteinase inhibitor compounds

Compounds of the formula (I): wherein R, R, R, R, R, R, p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation

Compounds of the formula (I): wherein R, R, R, p, q, and X are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors

Compounds of formula (I), wherein R, p, R, q, Rand Rare defined within, and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man

Pyrimidine derivatives

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Compounds

This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.

Growing community of inventors

Macclesfield, United Kingdom

Nicholas John Newcombe